Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality Jean-François Morère Editorial 01 December 2010 Pages: 229 - 230
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial David RossiDonatella DennettaS. Luzi Fedeli Original Research 02 October 2010 Pages: 231 - 235
Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice Yixiang WangLing DongShenglin Li Original Research 18 November 2010 Pages: 237 - 243
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 James F. SpicerSarah M. Rudman Review 24 June 2010 Pages: 245 - 255
Examining the safety profile of angiogenesis inhibitors: implications for clinical practice Martin Reck Review 15 September 2010 Pages: 257 - 267
Targeting mTOR in cancer: renal cell is just a beginning Hamdy AzimHatem A. Azim Jr.Bernard Escudier Review 20 June 2010 Pages: 269 - 280
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy James J. DriscollRoopa DeChowdhury Review 27 November 2010 Pages: 281 - 289
Use of rituximab in three children with relapsed/refractory Burkitt lymphoma Sinan AkbayramMurat DoğanAhmet Faik Öner Day-to-Day Practice 22 September 2010 Pages: 291 - 294
Tufted hair folliculitis in a woman treated with trastuzumab Ilana S. RosmanMilan J. Anadkat Day-to-Day Practice 15 October 2010 Pages: 295 - 296